Abstract. Axon injury following cerebral ischemia has received little scientific attention compared to the abundance of information dealing with the pathophysiology of grey matter ischemia. There are differences in the initial response of grey and white matter to ischemia in vitro. In this study we investigate whether the vasoactive peptide, endothelin-1, can generate a focal ischemic lesion in the white matter and compare the findings with endothelin-1-induced lesions in the grey matter. Using a minimally invasive technique to microinject endothelin-1 into selected brain regions, we observed an acute reduction in local MRI perfusion in the injected hemisphere after 1 hour. Twenty-four hours after microinjection of 10 pmoles of endothelin-1, we observed a loss of neurons in the grey matter. At 72 hours, neutrophils were absent and a macrophage/ microglia response and astrocyte gliosis were detected. No breakdown in the blood-brain barrier was detected. After injection of 10 pmoles endothelin-1 into the cortical white matter, we observed prolific amyloid precursor protein-positive immunostaining (indicative of axonal disruption) and an increase in tau-1 immunostaining in oligodendrocytes at 6 hours. Similar to the grey matter lesions, no neutrophils were present, a macrophage/microglia response did not occur until 72 hours and there was no disruption in the blood-brain barrier. Focal injections of endothelin-1 into specific areas of the rat CNS represent a model to investigate therapeutic approaches to white matter ischemia.
INTRODUCTION
Endothelin-1 (ET-1), originally isolated from porcine aortic endothelial cells, is a 21-amino acid peptide that possesses powerful and long-lasting vasoconstrictive effects in different vascular beds (1, 2) . ET-1 acts through specific receptors, which are widely distributed throughout the CNS on the vascular endothelium, as well as being present on neurons (2), astrocytes (3) , and microglia (4) .
In the rat CNS, endothelin type A receptors (ETA) are present on smooth muscle cells of pial arteries of the cerebral cortex (5) . ET-1 acts as a potent vasoconstrictor on large and small cerebral arteries in this vascular bed. For example, following topical application of ET-1 to the exposed middle cerebral artery there is a significant reduction in the cerebral blood flow to pathological levels in the brains of rats and cats (6, 7) . When applied directly to the circulation of goats, ET-1 decreased cerebral blood flow and increased cerebrovascular resistance in a dosedependent manner (8) . High doses of ET-1 (430 pmoles) injected directly into the brain parenchyma of rats have been reported to produce a 60% reduction in striatal blood flow within 20 min, without changes in systemic blood pressure (9) . Blood flow in this model was decreased 4 min after ET-1 injection and remained reduced for up to 3 hours.
Endothelin type B receptors (ETB) have been identified in the human cerebral cortex (10) , hippocampus (11) , and in the rat striatum (12) . It has been suggested that the ETB receptors are associated with resting and reactive astrocytes, activated microglia (5, 13) , and are expressed on some populations of neuronal cells (14) .
Studies in vitro have shown that ET-1 is not directly neurotoxic (15, 16) . However, in an ischemic environment in vivo ET-1 may exacerbate neuronal death indirectly through the excessive release of potentially neurotoxic mediators, such as glutamate from astrocytes (17) .
Despite the fact that white matter damage is a very important component of an ischemic insult, there are relatively few studies investigating the mechanisms of white matter injury compared to investigations into the effect of ischemia in grey matter. For example, there are only a few studies investigating axonal injury in white matter tracts in in vivo models of ischemia, such as the middle cerebral artery occlusion model (18, 19) , compared to the extensive literature focussing on neuronal damage in this model (20) . Stys et al studied the effects of ischemia on the rat optic nerve and spinal cord in vitro and showed that grey and white matter have different early responses (21) .
Excitotoxic activation of N-methyl-D-aspartate (NMDA) receptors is the initial event in grey matter ischemia. Axons do not express NMDA receptors but do possess ␣-amino-3-hydroxy-5-methyl-4-isoxzole propionic acid (AMPA)-kainate receptors. Activation of the AMPA receptors and reversal of the Na ϩ -Ca 2ϩ exchanger are important initial events in white matter ischemia (21) . Anoxia, ischemia, or trauma may also disrupt the function of other components of the white matter, including Tau-1 Damaged oligodendrocytes Chemicon (59) astrocytes, oligodendrocytes, and the myelin sheath. Excess glutamate can also signal through AMPA receptors present on oligodendrocytes and astrocytes to induce excitotoxic damage (22) . Compromise of the supporting glia and myelin sheath would be expected to adversely affect the structure and function of the axon.
In the present study, we used focal injections of ET-1 directly into the cortical white matter to study the effect of ischemia. We examined the integrity of axons in the cortical white matter using an immunohistochemical approach. This technique relies on the detection of the amyloid precursor protein (APP) accumulation in the axon end bulbs that form after injury. We compare the inflammatory profile and tissue damage to that following ET-1 injection directly into the striatum, which is comprised of both grey matter and smaller white matter fiber tracts.
MATERIALS AND METHODS

Reagents
Unless otherwise stated, all of the reagents used throughout were supplied by Sigma-Aldrich Company (Dorset, UK).
Stereotaxic Injections of ET-1
All experimental procedures involving animals were carried out in accordance with the Animals Scientific Procedures Act (1986) under Home Office approval, in the United Kingdom or approved by the ''Kantonales Veterinäramt, Basel,'' in Switzerland.
Adult male Wistar rats (Charles River, Margate, UK) were anesthetized with 2% isoflurane (Rhodia Organique Fine Ltd., Bristol, UK) in 70/30 (by volume) nitrous oxide/oxygen mixtures, placed on a stereotaxic frame, and maintained on 1% to 1.5% isoflurane for the remainder of the procedure. A rectal probe monitored body temperature and normothermia was maintained on a heated blanket (Homeothermic System, Harvard Apparatus, Edenbridge, UK). Using a minimally invasive stereotaxic procedure, 10 pmoles of porcine ET-1 was injected in volumes of 0.25 l or 1.0 l of sterile saline into the striatum (n ϭ 16), subcortical white matter (n ϭ 16), or cortex overlying the subcortical white matter (n ϭ 4). The following coordinates were used for stereotaxic injections: striatum: 1.0 mm anterior and 3.0 mm lateral to Bregma, ventral 4.5 mm from the surface of the brain; cortical white matter: 1.0 mm anterior, 2.0 mm lateral to Bregma, ventral 2.0 mm; cortex: 1.0 mm anterior, 2.0 mm lateral to Bregma, ventral 1 mm. Vehicle controls (sterile saline) were performed for each brain region (n ϭ 12).
MRI Measurements
All experiments were performed on a Biospec 47/15 system (Bruker, Ettlingen, Germany) equipped with a 4.7T horizontal bore (15 cm) magnet, Avance electronics and an 85 mm innerdiameter self-shielded gradient system capable of switching 130 mT/m in 150 seconds. The radiofrequency probe was a birdcage resonator of 35 mm inner diameter and a length of 50 mm.
Infarct volumes were determined 24 hours following ET-1 injections by means of quantitative in vivo MRI. Briefly, the rats were anesthetized with 1% to 1.5% isoflurane delivered by facemask and positioned with their heads in a 20-mm resonator. Each animal was then subjected to 1 imaging cycle in which 10 contiguous T2-weighted transverse slices of the brain (1.0-mm thick) were taken using a RARE sequence (optimized parameters: repetition time TR ϭ 4000 ms; effective echo time TE ϭ 66 ms; field-of-view (FOV) ϭ 40 ϫ 40 mm 2 , matrix dimension (MD) ϭ 256 ϫ 128 for data acquisition, and 2562 for image reconstruction. The total measuring time was 5 min. Quantitative morphometrical evaluation of single MRI slices was performed using a semi-automatic image analysis software (Imaging Research, St. Catherines, Canada). The damaged tissue was segmented by setting an intensity threshold. Infarct volume was calculated based on the damaged area in each slice and the distance between slices.
Cerebral blood flow (CBF) maps were obtained 1 and 3 hours after lesioning using the MRI bolus-tracking method analyzing the signal attenuation caused by the first pass of an intravascular contrast agent (23) . A single slice gradient echo sequence has been used with the following parameters: FOV ϭ 40 ϫ 40 mm The lesion area appears bright and is marked with an arrow (B). Coronal brain sections (arrows indicate site of injection) illustrating there is no detectable change in vessel permeability to HRP following injections of 10 pmoles ET-1 into the striatum at 24 hours. The arrowhead points to the choroid plexus, which has no BBB and is positively stained for HRP (C). Coronal brain sections stained with cresyl violet 24 hours following injections of 10 pmoles ET-1 into the striatum. The neuronal loss clearly demarcates the lesion, which is highlighted by an asterisk (D).
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SA, Roissy, France) (i.e. dextrane-coated iron-oxide nanoparticles) was administered at a rate of 2.5 mg/second using a spectrometer-controlled infusion pump during images 9 and 10. The total amount administered was 5 mg. Sections were recorded at 3, 6, 9, and 12 mm anterior to the intra-aural line (20) . The local tracer concentration in the tissue at time was computed from the MRI signal attenuation according to ci(t) ϰ [-ln[Si(t)/Si(pre)], where Si(pre) and Si(post) represent the signal intensity in the i-th voxel at prior and at time t after administration of Endorem. Relative perfusion values for each pixel were then obtained from the first and zero moment of the variate fit of the concentration-time curve, as previously described (24) . Quantitative analysis was carried out for ipsi-and contralateral regions of interest in cerebral cortex and striatum.
Permeability of the blood-brain barrier was assessed 3 hours after lesioning by analyzing the extravasation of the extracellular contrast agent Doterem (Laboratoire Guerbet SA). Ten contiguous T1-weighted transverse slices of the brain (1.0-mm thick) were taken using a spin echo sequence with the parameters TR ϭ 300 ms, effective echo time TE ϭ 20 ms, FOV ϭ 40 ϫ 40 mm 2 , MD ϭ 256 ϫ 128 for data acquisition and 256 2 for image reconstruction, NA ϭ 4. The total measuring time was 4 min. T1-weighted images were recorded 10 min after administration of 0.5 mmole/kg Dotarem. Image analysis was carried out by comparing MR signal intensities in ipsi-and contralateral striatal regions of interest.
Immunohistochemistry
At varying time points after surgery (between 6 hours and 2 weeks), rats were deeply anesthetized with Sagatal (Rhone Merieux, Harlow, Essex, UK) and transcardially perfused with heparinized saline alone or heparinized saline followed by perfusion-fixation with Bouin's fixative (5 ml acetic acid, 25 ml 40% formaldehyde, 75 ml picric acid). The brains were quickly removed and processed for embedding in paraffin wax or unfixed brains were embedded in Tissue Tek (OCT embedding compound Miles Inc, Elkhart, IN) and frozen in isopentane cooled on dry ice. Wax embedded tissues were cut on a microtome (10 m) and fresh-frozen tissues were sectioned on a cryostat (10 m). Immunocytochemistry was carried out as described previously (25, 26) . The primary antibodies used are listed in the Table. Briefly, dewaxed sections were microwaved on full power (2 ϫ 5 min) in citrate buffer and rinsed in 0.1 M phosphate buffered saline containing 0.1% Tween-20 (PBS/T). Fresh tissue sections were postfixed in absolute ethanol (4ЊC) for 10 min and washed in PBS/T. To eliminate endogenous peroxidase activity, the tissue was quenched in methanol containing 0.3% H 2 O 2 solution for 20 min. The tissue was blocked for 30 min in 10% normal serum derived from the species in which the secondary antibody was made (Vector Laboratories, Peterborough, UK). After blocking, the slides were incubated in the primary antibodies for 90 min at room temperature. The sections were then washed in PBS/T and incubated for 45 min with biotinylated secondary IgG followed by avidin-biotin-peroxidase complex (Vector) for 45 min. The binding of the ABC complex was revealed using 3,3-diaminobenzidine solution (brown precipitate). Negative controls omitting the primary antibody were used in each case. All sections were counterstained with hematoxylin (paraffin embedded) or cresyl violet (fresh frozen), dehydrated, and coverslipped.
Images were captured on a PC using LeicaQwin software (Leica Microsystems [UK], Milton Keynes, UK). Sections from representative lesions at different times in the evolution of the lesions were selected. Reconstructions of these lesions were then made using a Leitz drawing tube. For immunohistochemical analysis, each treatment group had at least 3 animals.
Assessment of Blood-Brain Barrier Permeability
The integrity of the blood-brain barrier (BBB) at 6, 12, and 24 hours and at 3 and 7 days after ET-1 injections into the grey and white matter was investigated (n Ն 2 for each time point). Thirty min prior to perfusion, animals were injected intravenously with type II horseradish peroxidase (HRP) 10 4 U/kg, under isoflurane anesthetic, as a tracer of increased BBB permeability. Coronal free-floating sections (50 m) were cut and a modified Hanker-Yates reaction (27) was used to detect the HRP.
RESULTS
Microinjection of 10 pmoles ET-1: Changes in Blood
Flow and Blood-Brain Barrier Integrity
We used a minimally invasive technique to microinject vehicle or 10 pmoles of ET-1 into the striatum. We observed an acute reduction in local MRI perfusion in the injected striatum at 1 hour as a consequence of ET-1 injections into the brain, which returned to normal by 3 hours (Fig. 1A) . We assessed local changes in cerebral perfusion by calculating the ratio of regional cerebral blood flow (rCBF) within a region of interest in the injected striatum versus a matched area in the noninjected striatum of the same animal. Following injection of 10 pmoles ET-1, the rCBF was reduced by ϳ40% at 1 hour and ϳ20% at 3 hours (Fig. 1A) . Pilot experiments revealed that there was no evidence of vascular occlusion by leukocytes at this time (data not shown). On T2-weighted MR images, a hyperintense area in the injected striatum was clearly demarcated 24 hours after ET-1 injections (Fig. 1B, arrows) , with a mean volume of 17.5 Ϯ 2.5 l (n ϭ 4). However, contrast-enhanced T1 weighted images did not reveal any signal enhancement in the injected striatum. Signal enhancement would have been indicative of extravasation of contrast agent and, hence, of increased BBB permeability. This finding was confirmed by the postmortem detection of intravenously administered HRP, an inert tracer used to examine the integrity of the BBB. Following injection of vehicle (1l saline) or 10 pmoles of ET-1 into the striatum the BBB remained impermeable to the HRP tracer at all time points examined, indicating that there was no BBB disruption (Fig. 1C) . We speculate that the increase in T2-hyperintensity is likely to be indicative of cytotoxic edema, as it is our experience that the initial T2-hyperintensity associated with the intracerebral injection volume persists for less than 1 hour. antibody (A, C, E, G, I) . Immunostaining with the neuron-specific marker, anti-Neu N, confirmed the loss of virtually all neurons within the striatum by 24 hours (B). No neutrophils (anti-HB199) were detected in the lesion (D). A significant number of ED-1-positive macrophages/activated microglia were detected throughout the lesion site from day 3 (F). GFAP-positive astrocytes were absent from the lesion site, but around its perimeter astrocytes upregulated expression of GFAP at day 3 (H). Disruption of myelin basic protein within white matter bundles (arrow) was observed at day 1 (J). Scale bars ϭ 100m.
Immunohistochemical Characterization of ET-1-Induced Lesion in the Grey Matter
Following injection of 10 pmoles of ET-1, neuronal death, which was confined to the striatum, was evidenced at 6 hours by a loss of Nissl substance and the appearance of hyperchromatic nuclei. At 24 hours, an area of neuronal loss was clearly visible as a loss of Nissl substance (Fig. 1D) and loss of NeuN staining ( Fig. 2A, B) . There was no recruitment of neutrophils at any of the time points examined, as assessed by cresyl violet staining and using the neutrophil-specific antibody HB199 (Fig. 2C,  D) . Using the monoclonal antibody ED-1, we observed a delayed activation and recruitment of resident microglia and macrophages within the area of neuronal death 3 days after the ET-1 injection (Fig. 2E, F) . Staining with an antibody directed against glial fibrillary acidic protein (GFAP) revealed a decrease in the number of GFAP-positive astrocytes present within the lesion but there was an increase in the intensity of staining of GFAP-positive astrocytes around the perimeter of the lesion site in the injected striatum at 3 days (Fig. 2G, H) . The white matter tracts within the striatum stained positively for myelin basic protein (MBP). Disruption in MBP staining in some of the white matter tracts in the striatum was observed 3 days after ET-1 injection (Fig. 2I, J) .
Immunohistochemical Characterization of ET-1-Induced Lesion in the Cortical White Matter
To examine the effect of ischemia on axonal integrity we stereotaxically injected 10 pmoles ET-1 directly into the cortical white matter. The ET-1 was made up in a volume of 0.25 l, which restricted the effect of ET-1 to the cortical white matter and minimized damage of the surrounding grey matter. To detect axonal injury we used immunohistochemical localization of APP in axon end bulbs (28) . The distribution of the APP-positive (ϩve) elements following injection of ET-1 was examined at 6 hours and 1, 3, 7, and 14 days after the injection. At 6 and 24 hours, small APP ϩve elements (ranging in size from 0.4-5 m 2 ) were detected along the white matter tracts covering a linear distance of up to 350 m from the injection site (Fig. 3A, B) . At 3 and 7 days after injection of ET-1, the APP ϩve elements could still be detected at a linear distance of up to 200 m from the site of injection, but were generally larger in size (up to 20 m 2 ) and reduced in number when compared to APP immunostaining at 24 hours (Fig. 3C ). Very few, if any, APP ϩve elements were detectable after the injection of vehicle at any time point.
No neutrophils were present and there were few, if any, ED-1-positive cells detected in or around the white matter tracts at 6 or 24 hours (Fig. 3D, E) . This was consistent with our findings regarding the inflammatory response following ET-1 injections directly into the striatum. At later time points (3, 7, and 14 days), there was a significant macrophage/microglia response in and around the white matter tracts (Fig. 3F) . A reconstruction of the area showing the distribution of APP ϩve elements and ED-1-positive macrophages/microglia following ET-1 injection is shown in Figure 4 .
In the white matter tracts, the GFAP-positive astrocytes and myelin as assessed by anti-MBP immunostaining appear to be relatively normal up to 3 days (Fig. 3G, H) . At the later time points (7 and 14 days) there was an increase in GFAP-positive immunostaining in the grey matter surrounding the cortical white matter and within the cortical white matter (Fig. 3I) . The myelin appears disrupted, although there is no overt loss of MBP (data not shown). In the cortical white matter of naï ve and vehicle-injected brains we detected a small number of Tau 1-positive oligodendrocytes. Following ET-1 microinjection, Tau-1 was found to accumulate in cells with oligodendrocyte morphology, with the greatest staining observed at 6 and 24 hours (Fig. 3J, K) . At later time points (7 and 14 days), the oligodendrocytes present in ischemic lesion no longer expressed Tau-1 (Fig. 3L) .
ET-1 (10 pmoles) Injections into the Cortex
Despite trying to localize the effect of ET-1 to the cortical white matter, we did observe some neuronal death in the grey matter above the cortical white matter. To ensure that neuronal loss observed in the cortex was not responsible for the resulting axonal damage detected in the white matter tracts, we injected ET-1 into the cortex to produce a lesion overlying the cortical white matter and investigated if there was any resultant axonal damage detected in the white matter tracts. We did not detect any APP ϩve elements throughout the In this study we set out to characterize focal ischemic lesions induced by stereotaxic injections of ET-1 in the grey or white matter. We have demonstrated a significant reduction in the relative cerebral blood flow 1 hour after ET-1 injections into the striatum, which was still reduced at 3 hours. These results are in accord with the findings of Fuxe et al, following an injection of 430 pmoles of ET-1 into the striatum. Using laser Doppler flowmetry they demonstrated a 60% reduction in striatal blood flow within an hour and a 40% reduction in basal blood flow 3 hours after an ET-1 injection (9). This significant decrease in rCBF will precipitate an ischemic insult. Ischemia is defined as the reduction of organ blood flow to a level sufficient to perturb its metabolism and function. The extent and duration of the reduction in rCBF defines the outcome. In experimental stroke models it has been shown that a reduction of 80% to 90% in cerebral perfusion over a relatively short duration of time (30 min or less) invariably results in energy failure and neuronal death (29, 30) . However, it has also been shown that less severe reductions in cerebral perfusion, if prolonged more than 3 hours, can lead to neuronal death (31) . In addition, spiny neurons in the striatum are known to be selectively vulnerable to ischemia, especially the dorso-lateral striatum, which is mainly affected in our model (32, 33) . It is clear that relatively brief and small reductions in rCBF lead to neuronal death.
Despite a significant reduction in rCBF and neuronal loss following an injection of 10 pmoles of ET-1 directly into the striatum, we did not detect breakdown of the BBB. The disruption of the BBB is believed to depend upon the level of rCBF during ischemia and the duration of ischemia (34) . In the rat, following a permanent occlusion of the middle cerebral artery (pMCAo) there is little disruption to the BBB (35) (35) . We observed a gradual return of blood flow in our model over at least 3 hours, which does not appear to induce a disruption in the BBB. Hence, this model will not be confounded by the contribution of vasogenic edema to lesion formation. Cell loss will contribute to cytotoxic edema, which is defined as cell swelling without any loss in the integrity of the BBB (36) .
Characterization of ET-1 Injections in the Grey Matter
Following formation of an ischemic lesion with 10 pmoles of ET-1 we observed no neutrophil infiltration at any of the time points examined. In numerous animal models of ischemia, the presence of neutrophils in the brain parenchyma has been detected between 12 and 48 hours following an ischemic insult (37) . Reports of neutrophils present in ischemic tissue following a stroke in man are far fewer (38, 39) , and it is generally assumed that lack of neutrophils in human ischemic lesions is because tissue samples were only obtained at late stages of ischemia. In our model it is clear that neutrophils are not always associated with the formation of an ischemic infarct. In the center of striatal ET-1 lesions we observed a reduction in the number of GFAP-positive astrocytes. This could be due to a downregulation of GFAP, or to death of the astrocytes. Following MCAo in the rat, there is a loss of GFAP mRNA and glial proteins within the infarct by 24 hours (40) . ET-1 does not appear to be directly toxic to astrocytes, as seen in primary cultures of rat cerebellum ET-1 (70 nmoles) that induced an increase in intracellular calcium in astrocytes but the cells remained viable (41, 42) . However, ET-1 has been shown to exert a direct effect on the reactive nature of astrocytes via ETB receptors after acute brain injury (43) . Around the perimeter of the lesion at day 3, astrocytes showed enhanced GFAP expression. Astrocyte gliosis is commonly associated with the borders of ischemic lesions (40) .
White Matter Ischemia
In man, ischemic episodes restricted to the white matter comprise 25% of all strokes seen clinically, and a large number of strokes are known to involve the white matter (44) . Despite this, experimental investigations into cerebral ischemia have primarily focused on damage to the grey matter. The disregard for the effect of ischemia on white matter tracts has been proposed as one of the reasons for the failure of promising preclinical pharmacological targets from in vivo stroke models into clinical therapy (20) . Recently the importance of white matter damage, as well as grey matter, in experimental stroke has been increasingly recognized. Compared to man, rodents have a much lower white/grey matter ratio. However, due to the cost efficiency and the availability of sequence data, antibodies, and genetically modified strains, rodents are preferred over other species (rabbits, cats, dogs, and sheep) in which white matter disruption is more comparable to human. A new model in the rat to study white matter ischemia would be extremely useful to investigate mechanisms of cell and axonal damage and potential protective approaches.
Characterization of ET-1 Injections in the White Matter
Following an ET-1 injection directly into the cortical white matter we observed numerous, small APP ϩve elements running along the white matter tracts as early as 6 hours. APP is transported down the axon by fast axonal transport (45) . Disruption of this transport mechanism, as the result of axonal injury, results in normally undetectable amounts of APP accumulating to an immunocytochemically detectable level within axonal end-bulbs. Closed head injury, spinal cord trauma, and multiple sclerosis in man (26, 46, 47) and traumatic brain injury and a delayed-type hypersensitivity reaction in rats (28, 48) are all examples of settings in which APP immunocytochemistry has been used to identify the presence of injured axons. Thus, APP immunocytochemistry permits injured axons to be detected soon after the injury and with considerable sensitivity.
At 6 or 24 hours no neutrophils were detected, very few activated macrophages or microglia were present in or around the injection site, and there was no overt decrease or increase in GFAP-immunoreactivity associated with astrocytes. In fact, responses from recruited leukocytes, microglia, and astrocytes were not detected until day 3. Despite the fact that myelin appeared intact until the later time points examined, oligodendrocytes showed enhanced Tau-1 staining throughout the lesioned cortical white matter from 6 hours. The staining was also detectable at 24 hours but was not observed at the later time points. Tau-1 immunoreactivity was shown to accumulate rapidly in damaged oligodendrocytes as early as 40 min following pMCAo in the rat (49) . Increased Tau-1 staining may reflect oligodendrocyte damage following ischemic injury. The impact of ischemia on oligodendrocytes requires further investigation.
Therefore, it appears that ET-1 injections have the potential to disrupt oligodendrocyte and axonal integrity prior to the recruitment of inflammatory cells, activation of resident microglia, or overt demyelination. Indeed, in this model, the presence of ED-1-positive macrophages and microglia, which were abundant at later time points, did not correlate with the amount of APP-positive elements detected. The recruited macrophages/activated microglia in the white matter did not appear to exacerbate the axonal damage as assessed by APP immunocytochemistry. In a more complex rat of model of thromboembolic stroke, APP immunocytochemistry also revealed positive elements within various white matter tracts at a distance from the overt pathology (50) . In contrast to the striatum, at 24 hours, in cortical white matter lesions GFAP-positive astrocytes appear normal. In the brain, regional differences in the sensitivity of astrocytes to ischemia have been reported (51) . In addition, it should be noted that the time and duration of ischemia may be different in the white matter.
Despite trying to localize the effect of ET-1 to the cortical white matter, we did observe some neuronal death in the overlying cortex. To determine if the neuronal loss observed in the cortex contributed to the axonal damage detected in the cortical white matter, we injected ET-1 to produce a lesion, which was confined to the cortex (52). This cortical lesion was not accompanied by APP ϩve immunostaining in the cortical white matter, suggesting that APP ϩve elements detected following injection of ET-1 into the white matter tract occur as a result of the action of ET-1 in the white matter rather than as a result of neuronal cell death in the overlying cortex and subsequent degeneration of their axons.
In summary, we have shown that microinjection of ET-1 into specific brain areas can be used to induce precise and reproducible focal ischemic lesions in grey or white matter, without disruption of the BBB. We have characterized the lesion in the grey and white matter using immunohistochemistry. We demonstrate neuronal and astrocyte loss in the striatal grey matter within 24 hours. This is accompanied by an atypical inflammatory response with no neutrophils present and delayed (72 hours) macrophage/microglia response. In the cortical white matter, we have shown that ET-1 injections induce axonal and oligodendrocyte disruption within 6 hours. Myelin damage and increased astrocyte reactivity is observed later at 72 hours.
Focal injection of ET-1 can be used as a tool to study the mechanisms of cytotoxic edema induced by ischemia in the grey and white matter areas of the CNS and to investigate the clinical potential of compounds in preserving axonal integrity.
